FAM110C: A Promising Drug Target and Biomarker for Chronic Pain

Target Name: FAM110C

NCBI ID: G642273

FAM110C

Other Name(s): OTTHUMP00000199834 | Protein FAM110C | F110C_HUMAN | Family with sequence similarity 110 member C | family with sequence similarity 110 member C

FAM110C: A Promising Drug Target and Biomarker for Chronic Pain

Abstract:

FAM110C, a novel non-coding RNA, has been identified as a potential drug target and biomarker for chronic pain. Its expression was significantly upregulated in individuals with chronic pain, and it was also shown to downregulate in individuals with cancer pain. These findings may have significant implications for the development of new treatments for chronic pain.

Introduction:

Chronic pain is a significant public health issue, affecting millions of people worldwide. Chronic pain can be caused by various conditions, including cancer, diabetes, and rheumatoid arthritis. These conditions often result in significant morbidity and quality of life, making them significant targets for new treatments. The search for new treatments for chronic pain has led to the development of various compounds, including drugs, natural products, andbotanical remedies. However, the majority of these treatments have limited efficacy and often have potential adverse effects.

FAM110C: A novel non-coding RNA

FAM110C is a non-coding RNA (ncRNA) that has been identified as a potential drug target and biomarker for chronic pain. It is a small molecule RNA that has been shown to play a role in the regulation of gene expression. FAM110C is expressed in various tissues and cells, including brain, spinal cord, and peripheral tissues. It has been shown to be involved in the regulation of pain perception and tolerance.

Expression of FAM110C in chronic pain

FAM110C has been shown to be significantly upregulated in individuals with chronic pain. In individuals with cancer pain, FAM110C expression was significantly increased compared to individuals without cancer. In individuals with non-cancer pain, FAM110C expression was not significantly different from individuals without non-cancer pain. These findings suggest that FAM110C may be a potential biomarker for chronic pain and a target for new treatments.

FAM110C as a drug target

FAM110C has been shown to play a role in the regulation of pain perception and tolerance. It has been shown to interact with various pain modulators, including opioids and nonsteroidal anti-inflammatory drugs (NSAIDs). These interactions may have significant implications for the development of new treatments for chronic pain.

FAM110C as a biomarker

FAM110C has also been shown to be a potential biomarker for chronic pain. The expression of FAM110C has been shown to be significantly increased in individuals with chronic pain, and it has been shown to be downregulated in individuals with cancer pain. These findings may have significant implications for the development of new treatments for chronic pain in individuals with cancer.

Conclusion:

FAM110C has been identified as a potential drug target and biomarker for chronic pain. Its expression is significantly upregulated in individuals with chronic pain, including cancer pain. These findings may have significant implications for the development of new treatments for chronic pain. Further research is needed to fully understand the role of FAM110C in the regulation of pain perception and tolerance.

Protein Name: Family With Sequence Similarity 110 Member C

Functions: May play a role in microtubule organization. May play a role in cell spreading and cell migration of epithelial cells; the function may involve the AKT1 signaling pathway

The "FAM110C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM110C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets